{"disease":{"id":"chronic-spontaneous-urticaria","name":"chronic spontaneous urticaria"},"drugs":{"marketed":[{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe chronic spontaneous urticaria in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07358364","title":"Remibrutinib in Real-world Clinical Practice","phase":"","overall_status":"RECRUITING","enrollment_count":3280,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03580356","title":"A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1078,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03580369","title":"A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1072,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04210843","title":"Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1033,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07021495","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","phase":"","overall_status":"RECRUITING","enrollment_count":840,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT05513001","title":"An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":696,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04426890","title":"To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":634,"lead_sponsor_name":"Celltrion","has_results":true},{"nct_id":"NCT07358780","title":"Remibrutinib in Real-world Clinical Practice - a US Sub-study","phase":"","overall_status":"RECRUITING","enrollment_count":505,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05030311","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06042478","title":"Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":470,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05032157","title":"A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":455,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06396026","title":"A Study of Efficacy and Safety of TLL-018 in CSU Participants","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":436,"lead_sponsor_name":"Hangzhou Highlightll Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03328897","title":"Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":418,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06868212","title":"A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07316114","title":"A Study to Describe the Real-world Effectiveness, Safety and Patterns of Use of Dupilumab in Patients With Chronic Spontaneous Urticaria","phase":"","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04180488","title":"Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT06365879","title":"To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":392,"lead_sponsor_name":"Taizhou Mabtech Pharmaceutical Co.,Ltd","has_results":false},{"nct_id":"NCT02477332","title":"Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":382,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07408219","title":"A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02161562","title":"OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":314,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03926611","title":"This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":311,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06250400","title":"Efficacy and Safety of Histamine Human Immunoglobulin in the Treatment of Chronic Spontaneous Urticaria (CSU)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Hangzhou Grand Biologic Pharmaceutical, Inc.","has_results":false},{"nct_id":"NCT04109313","title":"An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":229,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02649218","title":"A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05368285","title":"A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":208,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT06228560","title":"Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":202,"lead_sponsor_name":"Longbio Pharma","has_results":false},{"nct_id":"NCT07219615","title":"A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07328178","title":"Analysis of the Role of IgE Proteoforms in Health and Disease","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"KU Leuven","has_results":false},{"nct_id":"NCT04833855","title":"Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT07402213","title":"Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":180,"lead_sponsor_name":"Jemincare","has_results":false},{"nct_id":"NCT05107115","title":"Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04612725","title":"A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT06864507","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07415551","title":"Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Yuhan Corporation","has_results":false},{"nct_id":"NCT05795153","title":"A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06072157","title":"Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Allakos Inc.","has_results":false},{"nct_id":"NCT05936567","title":"Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT02550106","title":"Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06509334","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":135,"lead_sponsor_name":"Jemincare","has_results":false},{"nct_id":"NCT05528861","title":"A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Allakos Inc.","has_results":true},{"nct_id":"NCT05335499","title":"A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Taiho Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06991608","title":"A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":116,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06077773","title":"Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":113,"lead_sponsor_name":"Escient Pharmaceuticals, Inc","has_results":true},{"nct_id":"NCT06931405","title":"Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":105,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT06108869","title":"Improving Health and Wellbeing for People Diagnosed With Chronic Spontaneous Urticaria (CSU)","phase":"NA","overall_status":"SUSPENDED","enrollment_count":100,"lead_sponsor_name":"Royal College of Surgeons, Ireland","has_results":false},{"nct_id":"NCT05677451","title":"24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01723072","title":"Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05992987","title":"Assessment of Serum Levels of Adenosine Deaminase and Immunoglobulin E in Patients With Chronic Spontaneous Urticaria","phase":"","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT04210323","title":"Shotblocker® Use in Subcutaneous Injection","phase":"NA","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Saglik Bilimleri Universitesi","has_results":false},{"nct_id":"NCT06162728","title":"Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"Jasper Therapeutics, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}